Forbion raises €2.3 billion across two new funds
Forbion raised €2.3 billion ($2.6 billion) across its latest fundraising, marking the largest raise in the firm’s history and one of the largest global life sciences venture capital fundraisings over the past five years. The fundraising substantially exceeded its target, strengthening Forbion’s position as Europe’s largest dedicated life sciences venture capital firm, with approximately €7.5 billion in assets under management. The capital will be deployed through Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, which together can finance approximately 30 high-potential portfolio companies. The first investments have already been completed. Investors included MN, PGGM, KfW Capital, Ewing Marion Kauffman Foundation and Eli Lilly